{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T15:03:26Z","timestamp":1781535806515,"version":"3.54.5"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T00:00:00Z","timestamp":1694908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T00:00:00Z","timestamp":1694908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s13555-023-01030-x","type":"journal-article","created":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T15:01:22Z","timestamp":1694962882000},"page":"2869-2877","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0713-8283","authenticated-orcid":false,"given":"Axel","family":"De Greef","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romane","family":"Thirion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Dominique","family":"Ghislain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0499-7939","authenticated-orcid":false,"given":"Marie","family":"Baeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,17]]},"reference":[{"issue":"3","key":"1030_CR1","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s12016-021-08883-0","volume":"61","author":"C Zhou","year":"2021","unstructured":"Zhou C, Li X, Wang C, Zhang J. Alopecia areata: an update on etiopathogenesis, diagnosis, and management. Clin Rev Allergy Immunol. 2021;61(3):403\u201323. https:\/\/doi.org\/10.1007\/s12016-021-08883-0.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"1030_CR2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10238-020-00673-w","volume":"21","author":"A Sterkens","year":"2021","unstructured":"Sterkens A, Lambert J, Bervoets A. Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options. Clin Exp Med. 2021;21(2):215\u201330. https:\/\/doi.org\/10.1007\/s10238-020-00673-w. (Epub 2021 Jan 1).","journal-title":"Clin Exp Med"},{"issue":"1","key":"1030_CR3","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jaad.2020.06.047","volume":"85","author":"A Toussi","year":"2021","unstructured":"Toussi A, Barton VR, Le ST, Agbai ON, Kiuru M. Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: a systematic review. J Am Acad Dermatol. 2021;85(1):162\u201375. https:\/\/doi.org\/10.1016\/j.jaad.2020.06.047.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1030_CR4","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/jdv.15994","volume":"34","author":"B Burroway","year":"2020","unstructured":"Burroway B, Griggs J, Tosti A. Alopecia totalis and universalis long-term outcomes: a review. J Eur Acad Dermatol Venereol. 2020;34(4):709\u201315. https:\/\/doi.org\/10.1111\/jdv.15994.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"18","key":"1030_CR5","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, Ohyama M, Kwon O, et\u00a0al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687\u201399. https:\/\/doi.org\/10.1056\/NEJMoa2110343.","journal-title":"N Engl J Med"},{"issue":"3","key":"1030_CR6","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40257-023-00764-w","volume":"24","author":"O Kwon","year":"2023","unstructured":"Kwon O, Senna MM, Sinclair R, et\u00a0al. Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol. 2023;24(3):443\u201351. https:\/\/doi.org\/10.1007\/s40257-023-00764-w.","journal-title":"Am J Clin Dermatol"},{"key":"1030_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19121","author":"J Zhan","year":"2023","unstructured":"Zhan J, Cao J, Chen F, Jin Y, Huang C. Real-data on the use of baricitinib in adolescents with severe alopecia areata. J Eur Acad Dermatol Venereol. 2023. https:\/\/doi.org\/10.1111\/jdv.19121. (Published online ahead of print, 2023 Apr 17).","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1030_CR8","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.jaad.2022.11.028","volume":"88","author":"A Moussa","year":"2023","unstructured":"Moussa A, Eisman S, Sinclair RD, Bhoyrul B. Treatment of alopecia areata of the beard with baricitinib. J Am Acad Dermatol. 2023;88(4):948\u201350. https:\/\/doi.org\/10.1016\/j.jaad.2022.11.028.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"1030_CR9","doi-asserted-by":"publisher","first-page":"e15845","DOI":"10.1111\/dth.15845","volume":"35","author":"Y Wang","year":"2022","unstructured":"Wang Y, Liu T, Li S, et\u00a0al. Efficacy and safety of baricitinib in patients with refractory alopecia areata. Dermatol Ther. 2022;35(12):e15845. https:\/\/doi.org\/10.1111\/dth.15845.","journal-title":"Dermatol Ther"},{"issue":"11","key":"1030_CR10","doi-asserted-by":"publisher","first-page":"4910","DOI":"10.1007\/s12325-022-02281-4","volume":"39","author":"T Bieber","year":"2022","unstructured":"Bieber T, Feist E, Irvine AD, et\u00a0al. A review of safety outcomes from clinical trials of baricitinib in rheumatology, dermatology and COVID-19. Adv Ther. 2022;39(11):4910\u201360. https:\/\/doi.org\/10.1007\/s12325-022-02281-4.","journal-title":"Adv Ther"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-01030-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-023-01030-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-01030-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T10:10:15Z","timestamp":1698487815000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-023-01030-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,17]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1030"],"URL":"https:\/\/doi.org\/10.1007\/s13555-023-01030-x","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,17]]},"assertion":[{"value":"3 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Pierre-Dominique Ghislain discloses his past participation as an investigator and as a scientific advisor for Lilly Eli. Pierre-Dominique Ghislain and Marie Baeck have previously participated as speakers in events sponsored by Lilly Eli. All of the authors declare that the present study was conducted in an independent manner.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study and data collection were conducted with the approval of the hospital and faculty institutional review board (Commission d\u2019Ethique Biom\u00e9dicale Hospitalo-Facultaire) of Universit\u00e9 catholique de Louvain (UCLouvain), Belgium. This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. The patients in this manuscript have given written informed consent to participate and for publication of their case details.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}